Literature DB >> 2245394

von Willebrand factor in head and neck cancer.

J D Sweeney1, K M Killion, C F Pruet, M B Spaulding.   

Abstract

Laboratory abnormalities in blood coagulation factors are common in patients with cancer but the significance is unknown. Twenty-eight patients with head and neck cancer were studied at the time of diagnosis. Twenty-five were advanced-stage (III or IV) patients. Levels of clotting factors, antithrombin III, and plasminogen were normal. Levels of von Willebrand factor (vWF), both antigenic and functional (ristocetin cofactor), were elevated. This group of patients were followed for a minimum of 41 months (median, 48 months). Fifteen patients died within the follow-up period. von Willebrand factor levels were significantly higher in these 15 than the 13 survivors. Extreme elevation of ristocetin cofactor (greater than 300 U/dl) was seen in six of the 15 patients who died and in none of the survivors. Plasma vWF is elevated in head and neck cancer and the level measured at the time of diagnosis may have prognostic and potentially therapeutic implications.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2245394     DOI: 10.1002/1097-0142(19901201)66:11<2387::aid-cncr2820661123>3.0.co;2-u

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  Impact of surgery and chemotherapy on von Willebrand factor and vascular endothelial growth factor levels in colorectal cancer.

Authors:  Ignasio Gil-Bazo; Ignacio Gil Bazo; Victoria Catalán Goni; Victoria Catalán González; Alvaro Alonso Gutiérrez; Javier Rodríguez Rodríguez; José Antonio Páramo Fernández; Juan de la Cámara Gómez; José Luis Hernández Lizoain; Jesús García-Foncillas López
Journal:  Clin Transl Oncol       Date:  2005-05       Impact factor: 3.405

2.  Plasma von Willebrand factor level as a prognostic indicator of patients with metastatic colorectal carcinoma.

Authors:  Wei-Shu Wang; Jen-Kou Lin; Tzu-Chen Lin; Tzeon-Jye Chiou; Jin-Hwang Liu; Chueh-Chuan Yen; Po-Min Chen
Journal:  World J Gastroenterol       Date:  2005-04-14       Impact factor: 5.742

3.  Role of von Willebrand factor in tumour cell-induced platelet aggregation: differential regulation by NO and prostacyclin.

Authors:  P Jurasz; M W Stewart; A Radomski; F Khadour; M Duszyk; M W Radomski
Journal:  Br J Pharmacol       Date:  2001-11       Impact factor: 8.739

4.  The clinical value of von Willebrand factor in colorectal carcinomas.

Authors:  Vera S Schellerer; Larissa Mueller-Bergh; Susanne Merkel; Robert Zimmermann; Dominik Weiss; Anne Schlabrakowski; Elisabeth Naschberger; Michael Stürzl; Werner Hohenberger; Roland S Croner
Journal:  Am J Transl Res       Date:  2011-09-23       Impact factor: 4.060

Review 5.  Hemostatic alterations in cancer patients.

Authors:  F R Rickles; M Levine; R L Edwards
Journal:  Cancer Metastasis Rev       Date:  1992-11       Impact factor: 9.264

6.  Prognostic value of preoperative von Willebrand factor plasma levels in patients with Glioblastoma.

Authors:  Giovanni Marfia; Stefania Elena Navone; Claudia Fanizzi; Silvia Tabano; Chiara Pesenti; Loubna Abdel Hadi; Andrea Franzini; Manuela Caroli; Monica Miozzo; Laura Riboni; Paolo Rampini; Rolando Campanella
Journal:  Cancer Med       Date:  2016-05-28       Impact factor: 4.452

7.  The role of ADAMTS-13 and von Willebrand factor in cancer patients: Results from the Vienna Cancer and Thrombosis Study.

Authors:  Hanna L Obermeier; Julia Riedl; Cihan Ay; Silvia Koder; Peter Quehenberger; Rupert Bartsch; Alexandra Kaider; Christoph C Zielinski; Ingrid Pabinger
Journal:  Res Pract Thromb Haemost       Date:  2019-05-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.